Frequently Asked Questions
Asia-Pacific dominates the neuronal migration disorder treatment market due to the rise in untapped opportunities in emerging markets, enhanced neurological centers, demand of minimally invasive surgeries and increased consciousness among the patients about the precautions to be taken and the proper medication to be followed.
Latest development in the neuronal migration disorder treatment market is - Sumitomo Dainippon Pharma and Otsuka announced a partnership and license agreement for four psychiatry and neurology compounds, namely ulotaront (SEP-363856), SEP-4199, SEP-378614, and SEP-380135.
Major companies in the neuronal migration disorder treatment market are Johnson and Johnson Services, Inc. (U.S.), Stryker (U.S.), Smith and Nephew plc (U.K.), B.Braun Melsungen AG (Germany), Boston Scientific Corporation (U.S.), GSK plc (U.K.), Lilly (U.S.), Abbott (U.S.), Stryker (U.S.), Integra LifeSciences (U.S.), Abbvie,Inc (U.S), LivaNova PLC (U.K.).
Rising Awareness For Disease Treatment & Increased Clinical Studies and Government Initiatives are the growth drivers of the neuronal migration disorder treatment market.
Type, product, treatment type, route of administration, distribution channel and end-user are the factors on which the neuronal migration disorder treatment market research is based.
